Has Consuelo Veronica David, MD received payments from drug or device companies?

Yes. Drug and device makers reported $3,752 in general payments to Consuelo Veronica David, MD across 102 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Consuelo Veronica David, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Consuelo Veronica David, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Consuelo Veronica David, MD

Dermatology · Torrance, CANPI 1689963340

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,421 of the $3,752 with a category attached, or 64.5%. 23 manufacturers reported payments, led by UCB, Inc. at 45.5% of the total. 2025 is the largest year on record at $1,856, 3.2 times the $582 reported in 2019.

$3,752in general payments, 2019–2025

Across 102 payments — averaging $36.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

UCB, Inc.$2K
Galderma Laboratories, L.p.$380
Amgen$247
Regeneron Healthcare Solutions, Inc.$225
Pfizer$187
AbbVie$169
plus $837 from 17 others

$17,760in research payments, 2019–2025

Across 8 payments — averaging $2220.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Janssen Research & Development, LLC$18K

What the payments were for

Consulting fees$1,30035%
Food & beverage$2,42165%
Education$311%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
UCB, Inc.	20	$1,705
Galderma Laboratories, L.p.	10	$380
Amgen	11	$247
Regeneron Healthcare Solutions, Inc.	5	$225
Pfizer	9	$187
AbbVie	8	$169
Sanofi	7	$166
Johnson & Johnson	4	$102
Lilly USA, LLC	3	$70
Dermavant Sciences, Inc.	4	$69
Novartis	3	$60
Ortho Dermatologics, A Division Of Bausch Health US, LLC	3	$58
LEO Pharma Inc.	2	$57
Sandoz	2	$48
E.r. Squibb & Sons, L.L.C.	2	$44
EPI Health, LLC	2	$36
DUSA Pharmaceuticals, Inc.	1	$34
Biofrontera Inc.	1	$26
Incyte Corporation	1	$22
Glenmark Therapeutics Inc.	1	$16
Sun Pharmaceutical Industries Inc.	1	$15
Mayne Pharma Commercial LLC	1	$10
Organon	1	$5

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Bimzelx$1,300
DUPIXENT$125

How this compares

$3,752 in reported general payments places this provider in the 60th percentile of 1,875 dermatology providers in California.

See all dermatology providers in California →

Medicare billing

Part B allowed, 2024

$131,076

Medicare patients

306

Services billed

1,406

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Dupixent SyringeDupilumab	13	$49,232
Fluocinonide	41	$1,887
Betamethasone Dipropionate	35	$1,697
Desonide	23	$1,016
Clobetasol Propionate	28	$1,007
Triamcinolone Acetonide	47	$614
Metronidazole	14	$443
Ciclopirox	13	$377
Doxycycline Hyclate	21	$322
Ketoconazole	24	$213
Mupirocin	21	$189
Gentamicin Sulfate	13	$129
ValacyclovirValacyclovir Hcl	14	$112
Hydrocortisone	26	$90
Doxycycline Monohydrate	12	$62

Paid to pharmacies, not to this prescriber.

Other dermatology in Torrance

Paul YamauchiSanta Monica$2.9M
Jennifer SoungSanta Ana$2.8M
Robert GreenbergLivermore$2.6M
Neal BhatiaSan Diego$2.5M
April ArmstrongLos Angeles$2.3M
Jeffrey CrowleyBakersfield$2.1M
Jashin WuCorona$2M
Raja SivamaniSacramento$1.9M
Tien NguyenFountain Valley$1.2M
Tina BhutaniSan Francisco$1.1M

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →